Literature DB >> 57101

Antigenicity of the M proteins of group A hemolytic streptococci: further evidence for shared determinants among serotypes.

M K Wittner.   

Abstract

Shared antigenic determinants between M proteins of group A streptococci appear to be widespread among serotypes. This is demonstrated by the ability of purified M proteins to absorb opsonic antibody from a variety of heterologous antisera prepared against whole cells or purified M proteins. This absorption procedure has the capacity to separate passive mouse protecting and passive hemagglutinating antibodies from opsonic antibodies measured in vitro. When whole cells or M proteins are used as heterologous absorbents, immunoglobulin may be recovered from the cells or precipitates. The recovered antibody has most of the opsonic and some of the precipitating qualities of the original unabsorbed serum, but hemagglutinating titers are significantly lower. These data provide additional evidence that shared antigenicity among M proteins can be the result of common antigenic determinants. Arguments are presented that these cross-reactions are not the result of a nonspecific protein fraction associated with purified M proteins.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 57101      PMCID: PMC420655          DOI: 10.1128/iai.13.2.634-642.1976

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  22 in total

1.  ANTIGENICITY OF THE M PROTEINS OF GROUP A HEMOLYTIC STREPTOCOCCI.

Authors:  E N FOX
Journal:  J Immunol       Date:  1964-11       Impact factor: 5.422

2.  The indirect bactericidal test as a means of identifying antibody to the M antigen of Streptococcus pyogenes.

Authors:  W R MAXTED
Journal:  Br J Exp Pathol       Date:  1956-08

3.  Current knowledge of type-specific M antigens of group A streptococci.

Authors:  R C LANCEFIELD
Journal:  J Immunol       Date:  1962-09       Impact factor: 5.422

Review 4.  M proteins of group A streptococci.

Authors:  E N Fox
Journal:  Bacteriol Rev       Date:  1974-03

5.  Cross-protection among serotypes of group A streptococci.

Authors:  S Bergner-Rabinowitz; I Ofek; M D Moody
Journal:  J Infect Dis       Date:  1972-04       Impact factor: 5.226

6.  Further characterization of purified fractions of M protein from a strain of group A, type 12 Streptococcus.

Authors:  K L Vosti; R H Johnson; M F Dillon
Journal:  J Immunol       Date:  1971-07       Impact factor: 5.422

7.  Antigens of Streptococcus mutans. I. Characterization of a serotype-specific determinant from Streptococcus mutans.

Authors:  I Van de Rijn; A S Bleiweis
Journal:  Infect Immun       Date:  1973-05       Impact factor: 3.441

8.  Mediation of cytotoxic effects of streptococcal M protein by nontype-specific antibody in human sera.

Authors:  E H Beachey; G H Stollerman
Journal:  J Clin Invest       Date:  1973-10       Impact factor: 14.808

9.  The occurrence of two M antigens in certain group A streptococci related to type 14.

Authors:  G G WILEY; A T WILSON
Journal:  J Exp Med       Date:  1961-02-01       Impact factor: 14.307

10.  Differentiation of group A streptococci with a common R antigen into three serological types, with special reference to the bactericidal test.

Authors:  R C LANCEFIELD
Journal:  J Exp Med       Date:  1957-10-01       Impact factor: 14.307

View more
  3 in total

1.  Heterogeneity of group A type-specific antibodies.

Authors:  A M El Kholy; K Hafez; N Guirguis; R R Facklam; D R Johnson; L Wannamaker
Journal:  Infect Immun       Date:  1980-03       Impact factor: 3.441

2.  Streptococcal M protein extracted by nonionic detergent. II. Analysis of the antibody response to the multiple antigenic determinants of the M-protein molecule.

Authors:  V A Fischetti
Journal:  J Exp Med       Date:  1977-10-01       Impact factor: 14.307

3.  Homologous and heterologous protection of mice with group A streptococcal M protein vaccines.

Authors:  M K Wittner; E N Fox
Journal:  Infect Immun       Date:  1977-01       Impact factor: 3.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.